Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carolyn Yung Ho, M.D.

Co-Author

This page shows the publications co-authored by Carolyn Ho and E. Orav.
Connection Strength

2.505
  1. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart. 2016 Nov 15; 102(22):1805-1812.
    View in: PubMed
    Score: 0.676
  2. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
    View in: PubMed
    Score: 0.240
  3. Baseline Characteristics of the VANISH Cohort. Circ Heart Fail. 2019 12; 12(12):e006231.
    View in: PubMed
    Score: 0.212
  4. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur Heart J Cardiovasc Imaging. 2018 10 01; 19(10):1109-1116.
    View in: PubMed
    Score: 0.195
  5. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart. 2017; 4(2):e000615.
    View in: PubMed
    Score: 0.183
  6. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. JAMA Cardiol. 2017 04 01; 2(4):419-428.
    View in: PubMed
    Score: 0.176
  7. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017 May; 187:145-155.
    View in: PubMed
    Score: 0.175
  8. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015 Feb; 3(2):180-8.
    View in: PubMed
    Score: 0.149
  9. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013 Jun; 6(3):230-7.
    View in: PubMed
    Score: 0.135
  10. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013 May 01; 6(3):415-22.
    View in: PubMed
    Score: 0.133
  11. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012 Oct 01; 5(5):503-10.
    View in: PubMed
    Score: 0.128
  12. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009 Aug; 2(4):314-21.
    View in: PubMed
    Score: 0.103
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.